ClinicalTrials.gg
CompletedNCT06579092VISTAUpdated Dec 18, 2025

Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity

A Phase 2 interventional study of AZD5004 and Placebo in Obesity or Overweight, sponsored by AstraZeneca. Completed at 62 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 52 studies in Obesity by AstraZeneca — 8 open to participants now, 12 under way, 5 of them phase 3. Obesity · AstraZeneca.

Enrollment
9th of 50
310 · median 87
Started
2024
with 3 others
Phase 2
18 of 52
none open now
Registered
31st of 52
by date

Among the 52 studies in Obesity by AstraZeneca, this one is the 9th largest by enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2024, is one of 18 in phase 2, and was the 31st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 52 studies in Obesity by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Obesity by AstraZeneca, or all of them as a file.
02

Study summary

A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male and female participants at least 18 years of age who are living with obesity (body mass index [BMI] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) who have at least 1 weight-related comorbidity

Read the detailed description

This is a Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of 5 doses of AZD5004 compared with placebo, given once daily as an oral tablet or tablets for a duration of 36 weeks, in adults aged 18 years and above, who are living with obesity (BMI ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) and have at least 1 weight-related comorbidity (Hypertension, Dyslipidemia or hyperlipidemia, CV disease and/or Obstructive sleep apnea). Approximately 304 participants will be randomized in the study. The dual primary endpoints are percent change in body weight from baseline at 26 weeks and the proportion of participants with weight loss ≥ 5% of baseline weight at 26 weeks.

03

Conditions studied

  • Obesity or Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years of age.
  • of (a) ≥ 30 kg/m2, or (b) ≥ 27 kg/m2 and have a current diagnosis of at least 1 of the following weight-related comorbidities (treated or untreated):

    (i) Hypertension (ii) Dyslipidemia or hyperlipidemia (iii) CV disease (iv) Obstructive sleep apnea

  • A stable body weight for 3 months prior to Screening (± 5% body weight change).

Exclusion criteria

Exclusion Criteria:

  • Have obesity induced by other endocrine disorders, such as Cushing's syndrome or monogenic or syndromic obesity such as Prader-Willi syndrome.
  • Has received prescription or non-prescription medication for weight loss within the last 3 months prior to Screening.
  • Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier).
  • History of type 1 diabetes mellitus or type 2 diabetes mellitus.
  • inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper GI tract.
  • History of acute or chronic pancreatitis.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
310 participants (actual)

Study arms

  • Experimental
    Arm 1

    Active IMP

    Drug: AZD5004

  • Experimental
    Arm 2

    Active IMP

    Drug: AZD5004

  • Experimental
    Arm 3

    Active IMP

    Drug: AZD5004

  • Experimental
    Arm 4

    Active IMP

    Drug: AZD5004

  • Experimental
    Arm 5

    Active IMP

    Drug: AZD5004

  • Placebo comparator
    Arm 6

    Matching placebo for each of the 5 active arms

    Drug: Placebo

Interventions

  • AZD5004 film-coated tablet once daily during 36 weeks

    Also known as: Active IMP

  • DrugPlacebo

    Placebo matching AZD5004 film-coated tablet once daily during 36 weeks

06

What researchers measure

Primary outcomes

  1. Percent change in body weight from baseline

    To determine whether AZD5004 is superior to placebo for weight loss

    Time frame: 26 weeks

  2. Achieved Weight Loss ≥ 5% From Baseline

    To determine whether AZD5004 is superior to placebo on achieving weight loss ≥ 5% from baseline

    Time frame: 26 weeks

Secondary outcomes

  1. Percent change in body weight from baseline

    To determine whether AZD5004 is superior to placebo for weight loss

    Time frame: 36 weeks

  2. Achieved weight loss ≥ 5% from baseline

    To determine whether AZD5004 is superior to placebo on achieving weight loss ≥ 5% from baseline

    Time frame: 36 weeks

  3. Absolute change from baseline in body weight

    To determine whether AZD5004 is superior to placebo for absolute weight loss

    Time frame: Week 26 and Week 36

  4. Achieved weight loss ≥ 10% as well as ≥ 15% from baseline

    To assess the effect of AZD5004 versus placebo on achieving weight loss ≥ 10% as well as ≥ 15% from baseline

    Time frame: Week 26 and Week 36

07

Study locations

62 sites
  • Research Site
    Chandler, Arizona 85225, United States
  • Research Site
    Huntington Park, California 90255, United States
  • Research Site
    La Mesa, California 91942, United States
  • Research Site
    Lincoln, California 95648, United States
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Lombard, Illinois 60148, United States
  • Research Site
    Valparaiso, Indiana 46383, United States
  • Research Site
    West Des Moines, Iowa 50266, United States
  • Research Site
    Roslindale, Massachusetts 02131, United States
  • Research Site
    Farmington Hills, Michigan 48334, United States
  • Research Site
    Chesterfield, Missouri 63005, United States
  • Research Site
    Omaha, Nebraska 68134, United States
  • Research Site
    Vestal, New York 13850, United States
  • Research Site
    Durham, North Carolina 27701, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Fargo, North Dakota 58104, United States
  • Research Site
    Beachwood, Ohio 44122, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    North Charleston, South Carolina 29405, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Knoxville, Tennessee 37912, United States
  • Research Site
    Austin, Texas 78735, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    Houston, Texas 77040, United States
  • Research Site
    Woodway, Texas 76712, United States
  • Research Site
    Ogden, Utah 84405, United States
  • Research Site
    Charlottesville, Virginia 22911, United States
  • Research Site
    Manassas, Virginia 20110, United States
  • Research Site
    Heidelberg, 3081, Australia
  • Research Site
    Merewether, 2291, Australia
  • Research Site
    St Albans, 3021, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Calgary, Alberta T2V 4J2, Canada
  • Research Site
    Surrey, British Columbia V3T 2V6, Canada
  • Research Site
    Victoria, British Columbia V8V 4A1, Canada
  • Research Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Research Site
    Guelph, Ontario N1G 0B4, Canada
  • Research Site
    Hamilton, Ontario L8J 0B6, Canada
  • Research Site
    Hamilton, Ontario L8L 5G8, Canada
  • Research Site
    Toronto, Ontario M9V 4B4, Canada
  • Research Site
    Toronto, Ontario M9W 4L6, Canada
  • Research Site
    Terrebonne, Quebec J6X 4P7, Canada
  • Research Site
    Bad Oeynhausen, 32545, Germany
  • Research Site
    Berlin, 10787, Germany
  • Research Site
    Hamburg, 22607, Germany
  • Research Site
    Mannheim, 68167, Germany
  • Research Site
    Münster, 48145, Germany
  • Research Site
    Oldenburg, 23758, Germany
  • Research Site
    Sankt Ingbert, 66386, Germany
  • Research Site
    Suita-shi, 565-0853, Japan
  • Research Site
    Kaohsiung City, 807, Taiwan
  • Research Site
    Taichung, 40447, Taiwan
  • Research Site
    Tainan, 704, Taiwan
  • Research Site
    Taipei, 10048, Taiwan
  • Research Site
    Blackpool, FY3 7EN, United Kingdom
  • Research Site
    Bristol, BS34 6BQ, United Kingdom
  • Research Site
    Chesterfield, S40 4AA, United Kingdom
  • Research Site
    Leicester, Le5 4PW, United Kingdom
  • Research Site
    Rotherham, S65 1DA, United Kingdom
  • Research Site
    Witney, OX28 6JS, United Kingdom
08

References and documents

Publications

  • Davies MJ, Aroda VR, Rosenstock J, Capehorn M, Pedersen SD, Morizzo E, Malhotra S, Johansson PA, Grice D, Andersson A, Rizi EP, Sjostrom CD. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet. 2026 Jun 20;407(10547):2503-2514. doi: 10.1016/S0140-6736(26)00748-8. Epub 2026 Jun 8. PubMed 42259337 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Nov 2025, 13 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 13 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Aug 30, 2024
StartActual
Oct 8, 2024
Primary completionActual
Nov 21, 2025
CompletionActual
Nov 21, 2025
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06579092
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 30, 2024
Start date
Oct 8, 2024
Primary completion
Nov 21, 2025
Completion
Nov 21, 2025
Last update
Dec 18, 2025

Study contacts

Prof Melanie Davies, MBChB MD
principal investigator · Diabetes Research Centre Leicester Diabetes Centre - Bloom University of Leicester

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elecoglipron

Start the discussion